These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

93 related items for PubMed ID: 6368197

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Rhesus monkey cerebrospinal fluid amine metabolite changes following treatment with the reversible monoamine oxidase type-A inhibitor cimoxatone.
    Garrick NA, Seppala T, Linnoila M, Murphy DL.
    Psychopharmacology (Berl); 1985; 86(3):265-9. PubMed ID: 2412251
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Studies of selective and reversible monoamine oxidase inhibitors.
    Mann JJ, Aarons SF, Frances AJ, Brown RD.
    J Clin Psychiatry; 1984 Jul; 45(7 Pt 2):62-6. PubMed ID: 6429130
    [Abstract] [Full Text] [Related]

  • 9. The pharmacology of reversible monoamine oxidase inhibitors.
    Amrein R, Allen SR, Guentert TW, Hartmann D, Lorscheid T, Schoerlin MP, Vranesic D.
    Br J Psychiatry Suppl; 1989 Oct; (6):66-71. PubMed ID: 2695128
    [Abstract] [Full Text] [Related]

  • 10. Brofaromine (CGP 11 305 A) in treatment of depression: biological estimation of plasma concentrations.
    Fritze J, Becker T, Ziegler V, Laux G, Riederer P.
    Pharmacopsychiatry; 1990 May; 23(3):131-4. PubMed ID: 2374771
    [Abstract] [Full Text] [Related]

  • 11. Effect of moclobemide on clinical and neurochemical variables in depressed patients (preliminary findings).
    Stefanis CN, Alevizos B, Markianos M, Hatzimanolis J.
    J Neural Transm Suppl; 1988 May; 26():87-95. PubMed ID: 2452231
    [Abstract] [Full Text] [Related]

  • 12. Oral absorption and concentration-effect relationship of tyramine with and without cimoxatone, a type-A specific inhibitor of monoamine oxidase.
    Dollery CT, Brown MJ, Davies DS, Lewis PJ, Strolin-Benedetti M.
    Clin Pharmacol Ther; 1983 Nov; 34(5):651-62. PubMed ID: 6627826
    [Abstract] [Full Text] [Related]

  • 13. Brofaromine in depression: a Canadian multicenter placebo trial and a review of standard drug comparative studies.
    Chouinard G, Saxena BM, Nair NP, Kutcher SP, Bakish D, Bradwejn J, Kennedy SH, Sharma V, Remick RA, Kukha-Mohamad SA.
    Clin Neuropharmacol; 1993 Nov; 16 Suppl 2():S51-4. PubMed ID: 8313397
    [Abstract] [Full Text] [Related]

  • 14. [Monoamine oxidase inhibitor in the treatment of attention deficit disorder of residual type. Apropos of a case].
    Parquet PJ, Servant D, Bailly D, Meurice JP.
    Encephale; 1988 Nov; 14(6):439-41. PubMed ID: 3068049
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Debrisoquine and dextromethorphan phenotyping and antidepressant treatment.
    Perault MC, Bouquet S, Bertschy G, Vandel S, Chakroun R, Guibert S, Vandel B.
    Therapie; 1991 Nov; 46(1):1-3. PubMed ID: 2020918
    [Abstract] [Full Text] [Related]

  • 18. Enhancement of 5-HT-induced anorexia: a test of the reversibility of monoamine oxidase inhibitors.
    Fletcher PJ, Yu PH.
    Psychopharmacology (Berl); 1989 Nov; 98(2):265-8. PubMed ID: 2502797
    [Abstract] [Full Text] [Related]

  • 19. Differential response patterns to MAO inhibitors and tricyclics.
    Nies A.
    J Clin Psychiatry; 1984 Jul; 45(7 Pt 2):70-7. PubMed ID: 6376487
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.